Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Natco Pharma Q4 PAT...

    Natco Pharma Q4 PAT plunges to Rs 120 crore

    GarimaWritten by Garima Published On 2019-05-28T09:45:27+05:30  |  Updated On 13 Aug 2021 3:40 PM IST

    The company's board has declared a third interim dividend of Rs 1.25 per equity share of Rs 2 each, resulting in a total dividend payout of Rs 6.25 per equity share for 2018-19, Natco Pharma said.


    New Delhi: Natco Pharma Monday reported a steep decline in consolidated profit after tax at Rs 120.4 crore for the quarter ended March 31, 2019. The company posted a profit after tax of Rs 299.7 crore for the year-ago period, Natco Pharma said in a filing to BSE.


    Total revenue stood at Rs 486.7 crore for the quarter under review. It was Rs 787.9 crore for the same period a year ago.


    Read Also: Setback: Delhi HC restricts Natco Pharma from manufacturing cancer drug Ceritinib


    The company's profit after tax for 2018-19 was at Rs 642.4 crore as against Rs 695.2 crore in the previous year.


    Total revenue for the last fiscal stood at Rs 2,224.7 crore. It was Rs 2,242.4 crore in 2017-18.


    The company's board has declared a third interim dividend of Rs 1.25 per equity share of Rs 2 each, resulting in a total dividend payout of Rs 6.25 per equity share for 2018-19, Natco Pharma said.


    Founded in 1981, the company is based in Hyderabad. The roots of the company go back to the founding of NATCO (Acronym for National Trading Company) Pharmaceutical Division in Kothur, Telangana.

    Read Also: Natco Pharma marketing partner gets USFDA approval for Nitroglycerin Sublingual Tablets

    BSEconsolidatedfourth quarter resultsNatconatco financial resultsNatco pharmaNatco Q 4New DelhiQ4revenueShares of Natco Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok